{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:07Z","timestamp":1790963587913,"version":"4.1.0"},"reference-count":79,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T00:00:00Z","timestamp":1428019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:p>The B\u2010cell receptor signaling pathway, which is critical to the development and maturation of normal B\u2010cells, is emerging as an attractive therapeutic target in B\u2010cell malignancies. Ibrutinib is a potent irreversible inhibitor of Bruton's tyrosine kinase (Btk), a key kinase important for signal transduction in the B\u2010cell receptor (BCR) pathway. In preclinical studies, ibrutinib potently bound to Btk, inhibited BCR signaling, and decreased tumor cell proliferation and survival in many B\u2010cell malignancy models. Excellent safety and efficacy data in clinical trials have led to US Food and Drug Administration (FDA) approval of ibrutinib for previously treated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), as well as CLL with 17p deletion. Ongoing clinical studies have also demonstrated great potency of ibrutinib in treating other types of non\u2010Hodgkin's lymphoma (NHL), including diffuse large B\u2010cell lymphoma (DLBCL), follicular lymphoma (FL), and Waldenstr\u00f6m's macroglobulinemia (WM). Combination of ibrutinib with chemoimmunotherapy and other promising novel agents in B\u2010cell malignancy therapy has also been under clinical investigation.<\/jats:p>","DOI":"10.1002\/cpt.85","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T17:44:20Z","timestamp":1428083060000},"page":"455-468","source":"Crossref","is-referenced-by-count":54,"title":["Targeting Bruton's tyrosine kinase with ibrutinib in B\u2010cell malignancies"],"prefix":"10.1111","volume":"97","author":[{"given":"Y","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medicine Rutgers New Jersey Medical School Newark New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LL","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RE","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ML","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA"},{"name":"Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,3]]},"reference":[{"key":"e_1_2_25_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.008"},{"key":"e_1_2_25_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2853"},{"key":"e_1_2_25_3_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_2_25_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0"},{"key":"e_1_2_25_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.10.5715"},{"key":"e_1_2_25_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.09.001"},{"key":"e_1_2_25_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-003921"},{"key":"e_1_2_25_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_2_25_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_2_25_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_25_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_2_25_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_25_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515361"},{"key":"e_1_2_25_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.131"},{"key":"e_1_2_25_15_1","unstructured":"Brett L.K.et al.Drug screening reveals that ibrutinib (PCI\u201032765) exhibits synergy with BCL\u20102 and proteasome inhibitors in models of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). ASH Annual Meeting and Exposition. Abstract #3080 (2013)."},{"key":"e_1_2_25_16_1","doi-asserted-by":"crossref","unstructured":"Portell C.A.et al.Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist ABT\u2010199 (GDC\u20100199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions. ASH Annual Meeting and Exposition. Abstract #509 (2014).","DOI":"10.1182\/blood.V124.21.509.509"},{"key":"e_1_2_25_17_1","doi-asserted-by":"crossref","unstructured":"Tesar B.et al.Effect of MYD88 mutation in CLL on IRAK4 and BTK inhibition in vitro. ASH Annual Meeting and Exposition. Abstract #4132 (2013).","DOI":"10.1182\/blood.V122.21.4132.4132"},{"key":"e_1_2_25_18_1","doi-asserted-by":"crossref","unstructured":"Wu C.C.N.et al.Inhibition of Wnt signaling by dimethyl fumarate results in in vitro and in vivo clearance of chronic lymphocytic leukemia cells and has additive activity with ibrutinib. ASH Annual Meeting and Exposition. Abstract #4683 (2014).","DOI":"10.1182\/blood.V124.21.4683.4683"},{"key":"e_1_2_25_19_1","doi-asserted-by":"crossref","unstructured":"Ponader S.et al.Activity of Bruton's tyrosine kinase (Btk) inhibitor PCI\u201032765 in mantle cell lymphoma (MCL) identifies Btk as a novel therapeutic target. ASH Annual Meeting and Exposition. Abstract #3688 (2011).","DOI":"10.1182\/blood.V118.21.3688.3688"},{"key":"e_1_2_25_20_1","doi-asserted-by":"crossref","unstructured":"Ou Z.et al.Single\u2010agent Bruton's tyrosine kinase (Btk) inhibitor and single\u2010agent carfilzomib induce cell apoptosis arrest cell growth and downregulate NF\u2010Kb activity in mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #4971 (2011).","DOI":"10.1182\/blood.V118.21.4971.4971"},{"key":"e_1_2_25_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"e_1_2_25_22_1","doi-asserted-by":"crossref","unstructured":"Ou Z.et al.Targeting BCR activated STAT3 by ibrutinib in mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #3079 (2013).","DOI":"10.1182\/blood.V122.21.3079.3079"},{"key":"e_1_2_25_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12206"},{"key":"e_1_2_25_24_1","article-title":"Combination of ibrutinib with ABT\u2010199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","author":"Zhao X","year":"2014","journal-title":"Br. J. Haematol."},{"key":"e_1_2_25_25_1","doi-asserted-by":"crossref","unstructured":"Zhang L.et al.Anti\u2010CD20 and B\u2010cell receptor\u2010mediated growth inhibition and apoptosis: a preclinical study of ibrutinib and rituximab combination therapy in mantle cell lymphoma in vitro and in vivo. ASH Annual Meeting and Exposition. Abstract #1774 (2014).","DOI":"10.1182\/blood.V124.21.1774.1774"},{"key":"e_1_2_25_26_1","doi-asserted-by":"crossref","unstructured":"Sahakian E.et al.Combination of ACY1215 a selective histone deacetylase 6 (HDAC6) inhibitor with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib represents a novel therapeutic strategy in mantle cell lymphoma (MCL). ASH Annual Meeting and Exposition. Abstract #1660 (2012).","DOI":"10.1182\/blood.V120.21.1660.1660"},{"key":"e_1_2_25_27_1","doi-asserted-by":"crossref","unstructured":"Hagiwara K. Hiroatsu Iida M. Miyata Y. Naoe T.&Nagai H.Combination of the histone deacetylase inhibitor vorinostat with a B\u2010cell receptor signaling inhibitor markedly decreases cyclin D1 expression in a mantle cell lymphoma cell line. ASH Annual Meeting and Exposition. Abstract #3631 (2014).","DOI":"10.1182\/blood.V124.21.3631.3631"},{"key":"e_1_2_25_28_1","doi-asserted-by":"crossref","unstructured":"Tabe Y.et al.Selective inhibitor of nuclear export selinexor (KPT\u2010330) and BCL2 inhibitor ABT\u2010199 enhance the anti\u2010lymphoma effect of btk inhibitor ibrutinib in mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #2254 (2014).","DOI":"10.1182\/blood.V124.21.2254.2254"},{"key":"e_1_2_25_29_1","doi-asserted-by":"crossref","unstructured":"Zoellner A.K.et al.Differential role of the B\u2010cell receptor pathway in diffuse large cell B cell lymphoma: temsirolimus has additive effects in combination with the BTK inhibitor PCI\u201032765 and PI3K inhibitor Cal101 but antagonizes bortezomib in GCB subtype. ASH Annual Meeting and Exposition. Abstract #1664 (2011).","DOI":"10.1182\/blood.V118.21.1664.1664"},{"key":"e_1_2_25_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2071"},{"key":"e_1_2_25_31_1","doi-asserted-by":"crossref","unstructured":"Kuo H.\u2010P.et al.Combination of ibrutinib and BCL\u20102 or SYK inhibitors in ibrutinib resistant ABC\u2010subtype of diffuse large B\u2010cell lymphoma. ASH Annual Meeting and Exposition. Abstract #505 (2014).","DOI":"10.1182\/blood.V124.21.505.505"},{"key":"e_1_2_25_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.024"},{"key":"e_1_2_25_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311846111"},{"key":"e_1_2_25_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-14-32"},{"key":"e_1_2_25_35_1","doi-asserted-by":"crossref","unstructured":"Dominici E.M.et al.Carfilzomib a second\u2010generation proteasome inhibitor in combination with the Btk inhibitor ibrutinib as a novel therapeutic regimen for treating double hit DLBCL. ASH Annual Meeting and Exposition. Abstract #1834 (2013).","DOI":"10.1182\/blood.V122.21.1834.1834"},{"key":"e_1_2_25_36_1","doi-asserted-by":"crossref","unstructured":"Yang G.et al.MYD88 L265P promotes survival of Waldenstrom's macroglobulinemia cells by activation of Bruton's tyrosine kinase. ASH Annual Meeting and Exposition. Abstract #897 (2012).","DOI":"10.1182\/blood.V120.21.897.897"},{"key":"e_1_2_25_37_1","doi-asserted-by":"crossref","unstructured":"Chaudhary D.et al.Synergistic blockade of activated B cell\u2010like DLBCL proliferation with a selective inhibitor of IRAK4 in combination with inhibition of the B\u2010cell receptor signaling network. ASH Annual Meeting and Exposition. Abstract #3833 (2013).","DOI":"10.1182\/blood.V122.21.3833.3833"},{"key":"e_1_2_25_38_1","doi-asserted-by":"crossref","unstructured":"Chitta K.S.et al.The selective Bcl\u20102 inhibitor ABT\u2010199 synergizes with BTK or proteasome inhibitors to induce potent cell death in preclinical models of bortezomib or ibrutinib\u2010resistant Waldenstr\u00f6ms macroglobulinemia. ASH Annual Meeting and Exposition. Abstract #1689 (2014).","DOI":"10.1182\/blood.V124.21.1689.1689"},{"key":"e_1_2_25_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396853"},{"key":"e_1_2_25_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.09.008"},{"key":"e_1_2_25_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12867"},{"key":"e_1_2_25_42_1","doi-asserted-by":"crossref","unstructured":"Kim E.et al.Activity of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI\u201032765) in B\u2010cell acute lymphoblastic leukemia (B\u2010ALL). ASH Annual Meeting and Exposition. Abstract #2569 (2012).","DOI":"10.1182\/blood.V120.21.2569.2569"},{"key":"e_1_2_25_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511154"},{"key":"e_1_2_25_44_1","doi-asserted-by":"crossref","unstructured":"Rotin L.E.et al.Ibrutinib sensitizes AML cells to ROS inducers via a BTK\u2010independent mechanism. ASH Annual Meeting and Exposition. Abstract #2226 (2014).","DOI":"10.1182\/blood.V124.21.2226.2226"},{"key":"e_1_2_25_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_25_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_25_47_1","doi-asserted-by":"crossref","unstructured":"O'Brien S.et al.The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI\u201032765) monotherapy demonstrates long\u2010term safety and durability of response in chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) patients in an open\u2010label extension study. ASH Annual Meeting and Exposition. Abstract #4163 (2013).","DOI":"10.1182\/blood.V122.21.4163.4163"},{"key":"e_1_2_25_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"e_1_2_25_49_1","doi-asserted-by":"crossref","unstructured":"Farooqui M.et al.Single agent ibrutinib (PCI\u201032765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p. ASH Annual Meeting and Exposition. Abstract #673 (2013).","DOI":"10.1182\/blood.V122.21.673.673"},{"key":"e_1_2_25_50_1","doi-asserted-by":"crossref","unstructured":"O'Brien S.et al.Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE\u2122\u201017 Trial. ASH Annual Meeting and Exposition. Abstract #327 (2014).","DOI":"10.1182\/blood.V124.21.327.327"},{"key":"e_1_2_25_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_25_52_1","doi-asserted-by":"crossref","unstructured":"Brown J.R.et al.Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma. ASH Annual Meeting and Exposition. Abstract #3331 (2014).","DOI":"10.1182\/blood.V124.21.3331.3331"},{"key":"e_1_2_25_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_2_25_54_1","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2014.32.15_suppl.7009","article-title":"A phase 1b\/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases","volume":"32","author":"Jaglowski S.M.","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_25_55_1","doi-asserted-by":"crossref","unstructured":"Sharman J.P.et al.Ublituximab (TG\u20101101) a novel glycoengineered anti\u2010CD20 monoclonal antibody in combination with ibrutinib is highly active in patients with relapsed and\/or refractory CLL and MCL; results of a phase II trial. ASH Annual Meeting and Exposition. Abstract #4679 (2014).","DOI":"10.1182\/blood.V124.21.4679.4679"},{"key":"e_1_2_25_56_1","doi-asserted-by":"crossref","unstructured":"Brown J.R.et al.Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL\/SLL: final results of a phase 1b study. ASH Annual Meeting and Exposition. Abstract #525 (2013).","DOI":"10.1182\/blood.V122.21.525.525"},{"key":"e_1_2_25_57_1","doi-asserted-by":"crossref","unstructured":"Pollyea D.A.et al.A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. ASH Annual Meeting and Exposition. Abstract #1987 (2014).","DOI":"10.1182\/blood.V124.21.1987.1987"},{"key":"e_1_2_25_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_25_59_1","doi-asserted-by":"crossref","unstructured":"Wang M.et al.Single\u2010agent ibrutinib demonstrates safety and durability of response at 2 years follow\u2010up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international multicenter open\u2010label phase 2 study. ASH Annual Meeting and Exposition. Abstract #4453 (2014).","DOI":"10.1182\/blood.V124.21.4453.4453"},{"key":"e_1_2_25_60_1","doi-asserted-by":"crossref","unstructured":"Wang M.et al.Efficacy and safety of single\u2010agent ibrutinib in patients with mantle cell lymphoma who progressed after bortezomib therapy. ASH Annual Meeting and Exposition. Abstract #4471 (2014).","DOI":"10.1182\/blood.V124.21.4471.4471"},{"key":"e_1_2_25_61_1","doi-asserted-by":"crossref","unstructured":"Wang M.L.et al.Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial. ASH Annual Meeting and Exposition. Abstract #627 (2014).","DOI":"10.1182\/blood.V124.21.627.627"},{"key":"e_1_2_25_62_1","doi-asserted-by":"crossref","unstructured":"Wilson W.H.et al.The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI\u201032765) has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B\u2010cell lymphoma (DLBCL): interim results of a multicenter open\u2010label phase 2 study. ASH Annual Meeting and Exposition. Abstract #686 (2012).","DOI":"10.1182\/blood.V120.21.686.686"},{"key":"e_1_2_25_63_1","doi-asserted-by":"crossref","unstructured":"Fowler N.H.et al.The Bruton's tyrosine kinase inhibitor ibrutinib (PCI\u201032765) is active and tolerated in relapsed follicular lymphoma. ASH Annual Meeting and Exposition. Abstract #156 (2012).","DOI":"10.1182\/blood.V120.21.156.156"},{"key":"e_1_2_25_64_1","doi-asserted-by":"crossref","unstructured":"Bartlett N.L.et al.Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial. ASH Annual Meeting and Exposition. Abstract #800 (2014).","DOI":"10.1182\/blood.V124.21.800.800"},{"key":"e_1_2_25_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70311-0"},{"key":"e_1_2_25_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"e_1_2_25_67_1","doi-asserted-by":"crossref","unstructured":"Christian B.et al.A phase I study of ibrutinib and lenalidomide in patients with relapsed and refractory B\u2010cell non\u2010Hodgkin's lymphoma. ASH Annual Meeting and Exposition. Abstract #4476 (2014).","DOI":"10.1182\/blood.V124.21.4476.4476"},{"key":"e_1_2_25_68_1","doi-asserted-by":"crossref","unstructured":"Treon S.P.et al.A prospective multicenter study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom's macroglobulinemia. ASH Annual Meeting and Exposition. Abstract #251 (2013).","DOI":"10.1182\/blood.V122.21.251.251"},{"key":"e_1_2_25_69_1","doi-asserted-by":"crossref","unstructured":"Vij R.et al.Ibrutinib single agent or in combination with dexamethasone in patients with relapsed or relapsed\/refractory multiple myeloma (MM): preliminary phase 2 results. ASH Annual Meeting and Exposition. Abstract #31 (2014).","DOI":"10.1182\/blood.V124.21.31.31"},{"key":"e_1_2_25_70_1","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1200\/jco.2014.32.15_suppl.7063","article-title":"Preliminary safety and efficacy of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL)","volume":"32","author":"Jones J.A","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_25_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482125"},{"key":"e_1_2_25_72_1","doi-asserted-by":"crossref","unstructured":"Herman S.E.M. Mustafa R.Z. Farooqui M.&Wiestner A.In vivo ibrutinib abrogates BCR\u2010dependent adhesion in tumor cells of patients with chronic lymphocytic leukemia. ASH Annual Meeting and Exposition. Abstract #1936 (2014).","DOI":"10.1182\/blood.V124.21.1936.1936"},{"key":"e_1_2_25_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"e_1_2_25_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_2_25_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"key":"e_1_2_25_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"e_1_2_25_77_1","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/jco.2014.32.15_suppl.7010","article-title":"Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single\u2010center experience of 267 patients","volume":"32","author":"Woyach J.A","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_25_78_1","doi-asserted-by":"crossref","unstructured":"Balasubramanian S.et al.Mutational analysis of patients with primary resistance to single\u2010agent ibrutinib in relapsed or refractory mantle cell lymphoma. ASH Annual Meeting and Exposition. Abstract #78 (2014).","DOI":"10.1182\/blood.V124.21.78.78"},{"key":"e_1_2_25_79_1","doi-asserted-by":"crossref","unstructured":"Burger J.A.et al.Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition. ASH Annual Meeting and Exposition. Abstract #866 (2013).","DOI":"10.1182\/blood.V122.21.866.866"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.85","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.85","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:28:36Z","timestamp":1699363716000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,3]]},"references-count":79,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/cpt.85"],"URL":"https:\/\/doi.org\/10.1002\/cpt.85","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,3]]}}}